Skip to main content
Smart Investors Daily
NV

NASDAQ · NVCR

NovoCure Limited

Healthcare · Medical - Instruments & Supplies

$17.59

Up+$0.10 (+0.55%)

Updated Aug 13, 2026, 7:11 PM

SID Score

6.8/10

Composite research score

Smart Money

Institutional and insider signal

Market cap
1.53B
P/E ratio
-8.6
Dividend yield
0.00%
52-week range
$10.14 – $21.45
Volume
1.18M
Avg. volume
1.71M

Price performance

NVCR price history

1M range · 21 trading sessions · Daily adjusted prices

NVCR closed at $17.59 after 21 trading sessions, up 9.73% for the selected period.

Last close
$17.59
Period change
+9.73%
Period low
$14.84
Period high
$19.99
Daily close
View OHLC price history
NVCR OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Aug 12, 2026$17.66$17.675$17.22$17.591.18M
Aug 11, 2026$17.34$17.8255$17.29$17.66923.86K
Aug 10, 2026$16.27$17.59$16.27$17.311.05M
Aug 7, 2026$15.60$16.42$15.60$16.391.53M
Aug 6, 2026$16.20$16.20$15.58$15.69943.32K
Aug 5, 2026$16.14$16.25$15.925$16.051.23M
Aug 4, 2026$15.28$16.30$15.23$16.271.74M
Aug 3, 2026$15.00$15.69$15.00$15.321.64M
Jul 31, 2026$15.46$15.725$14.83$14.841.23M
Jul 30, 2026$15.20$15.49$15.045$15.231.41M
Jul 29, 2026$16.06$16.39$15.12$15.201.51M
Jul 28, 2026$16.99$17.05$16.155$16.311.38M
Jul 27, 2026$17.97$18.15$16.855$17.031.81M
Jul 24, 2026$20.68$21.4506$17.60$17.653.88M
Jul 23, 2026$18.00$20.55$18.00$19.998.95M
Jul 22, 2026$15.99$16.125$15.20$15.571.06M
Jul 21, 2026$15.91$16.41$15.84$16.001.07M
Jul 20, 2026$16.00$16.19$15.795$15.94933.51K
Jul 17, 2026$16.08$16.5199$15.8318$15.92856.32K
Jul 16, 2026$16.05$16.525$16.03$16.421.12M
Jul 15, 2026$15.52$16.06$15.31$16.031.1M

Latest NVCR news

The latest Smart Investors Daily articles mentioning NVCR.

NVCR research

Overview

Company profile and research snapshot.

Company profile

NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$28.25
Implied upside
Analysts
13
NVCR recent ratings
DateFirmRatingTarget
Jul 24, 2026WedbushNeutral
Jul 23, 2026HC Wainwright & Co.Buy
Jul 13, 2026JP MorganNeutral
Jun 18, 2026HC Wainwright & Co.Buy
May 4, 2026Wells FargoEqual-Weight
Open full forecast

News briefing

No generated briefing is available yet.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.